Health Condition 1: N951- Menopausal and female climactericstates
Conditions
Interventions
Intervention1: Fenavari 300 mg: Oral administration of two 150 mg capsules for 84 days
Intervention2: Fenavari 500 mg: Oral administration of two 250 mg capsules for 84 days
Control Intervention1: Pla
Sponsors
OmniActive Health Technologies
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects with menopause symptoms, defined as a score of greater or equal to 12 to lesser than equal to 32 in the Menopausal Rating Scale (MRS) at screening (includes both peri-menopausal and post-menopausal women) 2. Subjects who experience hot flashes and/or night sweats at least once per day 3. Subjects who experience at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes 4. Subjects with BMI between 18 and 40 kg/m at the time of screening 5. Subjects who agree to maintain their usual dietary habits and level of exercise i.e. maintain their usual lifestyle throughout the trial period 6. Subjects willing to refrain from taking any medications or preparations for addressing menopause symptoms, stress or anxiety or mood or sleep (herbal, dietary supplements, homeopathic preparations, etc.) during the study 7. Subjects willing to refrain from consuming alcohol 24 hours prior to the test days 8. Subjects willing to refrain from consuming caffeine and caffeine-containing products 12 hour prior to test days 9. Subjects willing to refrain from vigorous physical activity 12 hours prior to test days 10.Subjects willing to provide written consent 11. Subjects willing and able to understand and comply with the requirements of the study, consume the study IP as instructed, return for the required treatment period visits, comply with therapy prohibitions, and be able to complete the study
Exclusion criteria
Exclusion criteria: 1.Subjects having hypersensitivity or history of allergy to the study product 2.Subjects with a malignant disease or any concomitant end-state organ disease and/or laboratory abnormalities considered by investigators to be risky or that could interfere with data collection 3.Subjects suffering from a metabolic disorder (uncontrolled diabetes, uncontrolled thyroidal condition) and/or from severe chronic disease (cancer, renal failure, HIV, immunodeficiency, hepatic or biliary disorders, arthritis, uncontrolled cardiac disease) or from a disease found to be inconsistent with the conduct of the study by the investigator 4.Subjects with a psychiatric diagnosis including anxiety or depression 5.Subjects with sleep disturbances and/or are taking sleep aid medication 6.Subjects with history of using hormonal therapy for menopause 7.Subjects with uncontrolled hypertension (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg) at screening 8.Subjects who are on anxiolytics, anti-depressants, antipsychotics, anticonvulsants, centrally acting corticosteroids, opioid pain relievers, hypnotics, and/or prescribed sleep medications 9.Subjects who have excessive habitual caffeine consumption (greater than 300 mg caffeine/day or greater or qual to 3 cups of caffeinated coffee/day) throughout the study period 10.Subjects with a history of drug and /or alcohol abuse at the time of enrolment 11.Subjects who have been treated with any investigational drug or investigational device within a period of 3 months prior to study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change of menopause symptoms as assessed by MRSTimepoint: Baseline, Day 14, Day 28, Day 56 and Day 84 | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in AnxietyTimepoint: Baseline, Day 14, Day 28, Day 56 and Day 84;Mean change in MoodTimepoint: Baseline, Day 14, Day 28, Day 56 and Day 84;Mean change in Sleep QualityTimepoint: Baseline, Day 14, Day 28, Day 56 and Day 84;Mean change in the following Biomarkers: - Serum Estradiol - Progesterone - Follicle-Stimulating Hormone (FSH)Timepoint: Baseline,Day 56 and Day 84;Overall SafetyTimepoint: Baseline, Day 14, Day 28, Day 56 and Day 84 | — |
Countries
India
Contacts
Public ContactJestin V Thomas
Leads Clinical Research and Bio Services Pvt. Ltd.
Outcome results
None listed